The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | Magrolimab with azacitidine in patients with AML
Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase Ib study (NCT03248479) of magrolimab, an anti-CD47 antibody, in combination with azacitidine in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In this interview, Dr Daver focuses on the safety and efficacy data from the AML cohort. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
